Lycera banks $11M tranche for immunomodulator programs

Lycera has snapped up the second tranche of its Series A, banking $11 million and paving a new section of the road to the clinic for two new oral immunomodulating drugs. The second tranche lands almost exactly a year after the developer booked the first $10 million in a first round that totals $36 million. And Lycera CEO Bill Sibold tells FierceBiotech that "both programs are moving right on target, right at the pace we laid out." At this pace, he adds, Lycera will be in the clinic with its...